State Street Corp raised its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST – Free Report) by 19.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,167,353 shares of the company’s stock after purchasing an additional 526,028 shares during the quarter. State Street Corp owned 5.41% of Twist Bioscience worth $143,101,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also bought and sold shares of the company. Signaturefd LLC lifted its position in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the last quarter. EdgeRock Capital LLC bought a new stake in shares of Twist Bioscience in the 2nd quarter worth about $43,000. Blue Trust Inc. lifted its holdings in shares of Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of Twist Bioscience in the 2nd quarter worth about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after acquiring an additional 381 shares during the last quarter.
Twist Bioscience Stock Performance
NASDAQ TWST opened at $47.50 on Friday. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of -13.19 and a beta of 1.82. The company’s 50-day simple moving average is $44.94 and its two-hundred day simple moving average is $46.63. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90.
Insider Buying and Selling at Twist Bioscience
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on TWST. Barclays lowered their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Scotiabank raised their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 19th. TD Cowen restated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Finally, Robert W. Baird lifted their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $51.90.
Get Our Latest Stock Report on Twist Bioscience
Twist Bioscience Profile
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Featured Stories
- Five stocks we like better than Twist Bioscience
- How to Plot Fibonacci Price Inflection Levels
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- How to Use Stock Screeners to Find Stocks
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.